1415728-57-2Relevant articles and documents
Organocatalytic, enantioselective synthesis of VNI: A robust therapeutic development platform for Chagas, a neglected tropical disease
Dobish, Mark C.,Villalta, Fernando,Waterman, Michael R.,Lepesheva, Galina I.,Johnston, Jeffrey N.
, p. 6322 - 6325 (2012)
VNI is a potent inhibitor of CYP51 and was recently shown to achieve a parasitological cure of mice infected with T. cruzi in both acute and chronic stages of infection. T. cruzi is the causative parasite of Chagas disease, a neglected tropical disease. The first enantioselective chemical synthesis of VNI (at a materials cost of less than $0.10/mg) is described. Furthermore, the key enantioselective step is performed at the 10 g scale.